- Same Thing
- Side Effects
- What Is
- Drug Interactions
Are Imfinzi and Tecentriq the Same Thing?
Imfinzi (durvalumab) and Tecentriq (atezolizumab) Injection for intravenous infusion are monoclonal antibodies used to treat patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy; or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Side effects of Imfinzi and Tecentriq that are similar include fatigue, constipation, decreased appetite, nausea, swelling of extremities, urinary tract infection (UTI), abdominal pain, diarrhea/colitis, fever, shortness of breath, cough, and rash.
Side effects of Imfinzi that are different from Tecentriq include musculoskeletal pain.
Side effects of Tecentriq that are different from Imfinzi include vomiting, back or neck pain, joint pain, anemia, dehydration, itching, intestinal obstruction, urinary obstruction, blood in the urine (hematuria), acute kidney injury, venous thromboembolism, severe infection (sepsis), and pneumonia.
Both Imfinzi and Tecentriq may interact with other drugs.
What Are Possible Side Effects of Imfinzi?
Common side effects of Imfinzi include:
What Are Possible Side Effects of Tecentriq?
Common side effects of Tecentriq include:
- decreased appetite
- abdominal pain
- urinary tract infection
- swelling of the extremities
- back or neck pain
- joint pain
- intestinal obstruction
- urinary obstruction
- blood in the urine (hematuria)
- shortness of breath
- acute kidney injury
- venous thromboembolism
- severe infection (sepsis)
What Is Imfinzi?
Imfinzi (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy; or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
What Is Tecentriq?
Tecentriq (atezolizumab) Injection for intravenous infusion is a monoclonal antibody indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (cancer) who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
What Drugs Interact With Imfinzi?
Imfinzi may interact with other drugs. Tell your doctor all medications and supplements you use.
How Should Imfinzi be Taken?
Administer Imfinzi in a dose of 10 mg/kg as an intravenous infusion over 60 minutes every 2 weeks.
How Should Tecentriq be Taken?
The recommended dose of Tecentriq is 1200 mg administered as an intravenous infusion over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.
All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).
Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.
Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.
The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.
As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.
Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.
If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.
You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.
Genentech USA, Inc. Tecentriq Product Information.